← Eichor
Study identifier: NCT06830421 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

Condition: Primary Central Nervous System Lymphoma  ·  Sponsor: University Hospital Freiburg

PhasePhase 3
Planned participants340
Who can joinAll sexes, 65 Years to no upper limit
Healthy volunteersNo

About this study

Most patients being diagnosed with primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) are 60 years or older. Elderly patients with PCNSL have a poor prognosis and there is a great medical need to improve outcome for this vulnerable population. In Germany and many international centres, there are currently two widely used strategies to treat elderly PCNSL patients who are eligible for high-dose methotrexate (HD-MTX) treatment, which have not yet been compared head-to-head. The R-MP regimen has been established by the Cooperative PCNSL Study Group as a "conventional" immunochemotherapy standard treatment for elderly patients with newly diagnosed disease and consists of Rituximab, HD-MTX and Procarbazine followed by maintenance therapy with Procarbazine. In contrast, another recently established protocol also includes HD-MTX-based induction therapy, but followed by consolidating high-dose chemotherapy and autologous stem cell transplantation (HCT-ASCT). This is an overall more intensive, but substantially shorter treatment approach, feasible for elderly patients being considered eligible for a more intensive treatment. The PRIMA-CNS trial aims to compare these two treatment approaches with respect to survival, response rates and toxicity.

This description comes directly from the study's public registry record.

Talk to the study team

Elisabeth Schorb, MD  ·  +49 761 270-35360  ·  elisabeth.schorb@uniklinik-freiburg.de

Gerald Illerhaus, MD  ·  +49 711 278-30400  ·  g.illerhaus@klinikum-stuttgart.de

Always discuss trial participation with your own doctor first.

Locations (35)

University Hospital Freiburg, Department Medicine I, Hematology, oncology and stem cell transplantationFreiburg im Breisgau, Baden-Wurttemberg, GermanyRecruiting
Klinikum Stuttgart, Clinic of Hematology, Oncology and Palliative Care, Stuttgart Cancer Center / Tumor Center Eva Mayr-StihlStuttgart, Baden-Wurttemberg, GermanyRecruiting
University Hospital AachenAachen, GermanyRecruiting
University Hospital AugsburgAugsburg, GermanyRecruiting
Helios Klinikum Berlin-BuchBerlin, GermanyNot Yet Recruiting
University Hospital BerlinBerlin, GermanyRecruiting
Evangelisches Klinikum BethelBielefeld, GermanyNot Yet Recruiting
Universitätsklinikum Knappschaftskrankenhaus Bochum GmbHBochum, GermanyRecruiting
Städtisches Klinikum Braunschweig gGmbHBraunschweig, GermanyRecruiting
Klinikum Bremen-Mitte gGmbHBremen, GermanyRecruiting
Klinikum Chemnitz gGmbHChemnitz, GermanyNot Yet Recruiting
Universitätsklinikum KölnCologne, GermanyNot Yet Recruiting

+ 23 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06830421